CRISPR-like technique offers clues to mimic protective genetic mutations
Using a variation of CRISPR gene editing may be a potential strategy for mimicking the protective effects of a genetic mutation linked to lower cholesterol levels and heart disease risks, according to new mouse research from the Perelman School of Medicine at the University of Pennsylvania published this week in Circulation.
People with naturally occurring mutations that cause a loss of function in the gene for ANGPTL3 have reduced blood triglycerides, LDL cholesterol, and risk of coronary heart disease, with no apparent detrimental consequences to their health. This makes the ANGPTL3 protein an attractive target for new heart disease drugs. Earlier studies at Penn found that single copies of inactivating mutations in ANGPTL3 are found in about one in every 250 people of European heritage; however, people with mutations in both copies of the gene are more rare.
A team led by Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine, assessed in a mouse model whether base editing – a variation of CRISPR genome editing that does not require breaks in the double-strand of DNA – might be used in humans one day to introduce mutations into ANGPTL3 to reduce blood lipid levels.
“This proof-of-principle study showed that base-editing of ANGPTL3 is a potential way to permanently treat patients with harmful blood lipid levels,” Musunuru said. “It would be especially useful in patients with a rare condition called homozygous familial hypercholesterolemia, which causes sky-high cholesterol levels and dramatically increased risk of heart attack. They are very difficult to treat with today’s medications, and a one-time CRISPR ‘vaccination’ might be ready to use in these patients within five years.”
The study took a three-part approach. First, the team injected normal mice with the base-editing treatment for the ANGPTL3 gene. After a week, sequencing of the ANGPTL3 target site in liver samples from the mice revealed a median 35 percent editing rate in the target gene and no off-target mutations. In addition, the mean levels of blood lipids were significantly lower in the treated mice by up to 30 percent compared to untreated mice.
Second, the researchers compared mice with the modified ANGPTL3 gene to those injected with a base-editing treatment for another liver gene, PCSK9, for plasma cholesterol and triglycerides. After a week, ANGPTL3 targeting caused a similar reduction in cholesterol but a much greater decline in triglycerides compared to targeting PCSK9. The PCSK9 protein is the target of currently available medications, including evinacumab, which has been shown to reduce cholesterol (but not triglycerides) as well as the risk of heart attack and stroke.
Third, they looked at how base editing of the ANGPTL3 gene performed in a mouse model of homozygous familial hypercholesterolemia (in which knocking out PCSK9 had little effect). After two weeks, the treated mice showed substantially reduced triglycerides (56 percent) and cholesterol (51 percent) compared to untreated mice.
Musunuru’s lab is now preparing to test CRISPR-based treatments against the human ANGPTL3 gene in human liver cells transplanted into mice. This will provide important information on efficacy and safety that will be needed before human trials can move forward.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Creative Biogene Offers One-Stop Customized CRISPR Based Microbe Genome Editing Serviceon October 11, 2021 at 1:44 am
Creative Biogene Offers One Stop Customized CRISPR Based Microbe Genome Editing Service for global clients New York United States August 18 2021 Creative Biogene has been dedicated itself to ...
- Global Gene Editing Technologies Market Report Covers Methodology and Data Source with Market Size Estimation and Breakdown 2021 to 2027on October 8, 2021 at 3:19 am
Oct 08, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" The report analyse the growth rate of ...
- FDA stops all Allogene's CAR-T trials over safety scare, raising questions about future of gene editingon October 8, 2021 at 12:45 am
The FDA has sent shockwaves through the off-the-shelf CAR-T space, slapping a clinical hold on all of Allogene Therapeutics’ AlloCAR T clinical trials in response to an abnormality that could ...
- Gene editing can turn storage fat cells into energy-burning fat cellson October 7, 2021 at 5:21 am
A team of researchers at UT Southwestern Medical Center's Touchstone Diabetes Center have successfully used CRISPR gene editing to turn fat cells normally used for storage into energy-burning cells.
- The gene-editing engineer working to boost expertise in Chinaon October 6, 2021 at 8:33 am
The chief executive of Qihan Biotech aims to enable the first successful pig-to-human organ transplant and foster innovative biomedical research in her home country.
- Gene Editing Gave This Blind Woman Some of Her Vision Backon September 30, 2021 at 4:10 pm
OHSASimple tasks like riding a bike down the street or driving to the grocery store are a no-go for Carlene Knight. Afflicted with a rare genetic disease called Leber congenital amaurosis type 10 ...
- CRISPR Gene-Editing Experiment Partly Restores Vision In Legally Blind Patientson September 30, 2021 at 8:49 am
An experimental trial of seven patients with LCA, regained some of their vision after being legally-blind, through CRISPR gene-editing.
- What is gene editing and how could it be used to develop new food crops?on September 29, 2021 at 10:33 am
The government has announced plans to relax rules around gene editing, claiming it will enable easier research and development of more nutritious or pest-resistant food crops. But the relaxation of ...
- In vivo gene editing grabs the spotlight after Intellia triumph, but challenges loomon September 29, 2021 at 12:00 am
Investors are enthusiastic about the next generation of gene-focused treatments, most notably in vivo gene editing, which recently got a major boost from Intellia's positive first-in-human data. But ...
- England to ease regulations on gene editing in agricultural researchon September 28, 2021 at 11:53 pm
Britain's farming and environment minister George Eustice announced on Wednesday that regulations related to gene editing in agricultural research would be eased in England following a public ...
via Bing News